$1.77
-0.13 (-6.84%)
Open$1.73
Previous Close$1.90
Day High$1.79
Day Low$1.53
52W High$4.19
52W Low$1.09
Volume—
Avg Volume159.5K
Market Cap148.47M
P/E Ratio—
EPS$-1.97
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,617.5% upside
Current
$1.77
$1.77
Target
$30.40
$30.40
$22.94
$30.40 avg
$39.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.20M | 24.88M | 53.29M |
| Net Income | -251,430,959 | -1,320,959,060 | -9,463,863 |
| Profit Margin | -3,492.3% | -5,603.4% | -17.8% |
| EBITDA | -181,235,969 | -1,395,170,020 | -11,859,784 |
| Free Cash Flow | — | — | -9,841,834 |
| Rev Growth | +183.3% | -45.3% | -6.8% |
| Debt/Equity | 10.79 | 2.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |